Please assess the completion status of the following clinical trial:

Trial Title: A Study of Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Inadequately Controlled on Inhaled Corticosteroids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Body weight 40 kg--150 kg~* Chest radiograph with no evidence of clinically significant abnormality~* Uncontrolled asthma~Exclusion Criteria:~* Asthma exacerbation during screening~* Known malignancy~* Known immunodeficiency~* Pre-existing lung disease other than asthma~* Uncontrolled clinically significant medical disease~* Current smoker~* History of substance abuse that may impair or risk the patient's full participation in the study, in the judgment of the investigator~* Prior allergic reaction to a monoclonal antibody~* Patients (men and women) of reproductive potential who are not willing to use contraception~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).